Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase

K Pietilä; W T Hermens; A Harmoinen; T Baardman; A Pasternack; E J Topol; M L Simoons

doi:10.1016/s0002-9149(97)00606-1

Comparison of peak serum C-reactive protein and hydroxybutyrate dehydrogenase levels in patients with acute myocardial infarction treated with alteplase and streptokinase

Am J Cardiol. 1997 Oct 15;80(8):1075-7. doi: 10.1016/s0002-9149(97)00606-1.

Authors

K Pietilä¹, W T Hermens, A Harmoinen, T Baardman, A Pasternack, E J Topol, M L Simoons

Affiliation

¹ Clinic of Internal Medicine, Department of Clinical Sciences, Tampere University, Finland.

PMID: 9352981
DOI: 10.1016/s0002-9149(97)00606-1

Abstract

Peak serum C-reactive protein concentrations were measured in 146 patients randomized to receive streptokinase, alteplase, or a combination of streptokinase and alteplase in the GUSTO-I trial. Those receiving alteplase treatment had lower values than those receiving streptokinase or the combination treatment. Irrespective of treatment, complete reperfusion of the infarct-related artery (TIMI grade 3 flow) was associated with low peak serum C-reactive protein values.

Publication types

Clinical Trial
Comparative Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Aged
C-Reactive Protein / metabolism*
Drug Therapy, Combination
Female
Humans
Hydroxybutyrate Dehydrogenase / blood*
Male
Middle Aged
Myocardial Infarction / blood*
Myocardial Infarction / drug therapy
Streptokinase / therapeutic use*
Tissue Plasminogen Activator / therapeutic use*

Substances

C-Reactive Protein
Hydroxybutyrate Dehydrogenase
Streptokinase
Tissue Plasminogen Activator